Product Description
GMP approved factory,stable supplying, competitive price
AI Product Description
*The following content is generated by AI and is for reference only.
Baloxavir marboxil, often referenced in scientific contexts as Baloxavir INTS or simply baloxavir, is a potent antiviral medication developed specifically for the treatment of influenza. Its molecular formula is C24H18F3N5O7S, representing a complex structure designed to inhibit viral replication efficiently. The compound carries the CAS number 1965973-20-7, serving as its unique chemical identifier in global databases. Originally synthesized by Shionogi & Co., Ltd., this drug belongs to a novel class of antivirals known as cap-dependent endonuclease inhibitors. Unlike traditional neuraminidase inhibitors such as oseltamivir, baloxavir targets the PA subunit of the viral RNA polymerase complex, effectively blocking the "cap-snatching" mechanism required for viral mRNA synthesis.
The primary clinical application of baloxavir marboxil is the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than forty-eight hours. It is indicated for both adults and pediatric patients weighing at least five kilograms. A significant advantage of this therapy is its single-dose administration regimen, which markedly improves patient compliance compared to multi-day dosing schedules required by other flu medications. By inhibiting viral replication early in the infection cycle, it reduces the duration of symptoms and lowers viral shedding, thereby potentially decreasing transmission rates within communities.
Pharmacokinetically, baloxavir marboxil acts as a prodrug; upon oral ingestion, it undergoes rapid hydrolysis by intestinal esterases to release the active moiety, baloxavir acid. This active form achieves high concentrations in respiratory tissues, directly targeting the site of viral replication. While generally well-tolerated, clinicians must monitor for potential interactions with polyvalent cations found in dairy products or antacids, which can significantly reduce absorption. As influenza viruses continue to evolve, baloxavir represents a critical addition to the therapeutic arsenal, offering a distinct mechanism of action that remains effective against many strains resistant to neuraminidase inhibitors. Ongoing research continues to explore its efficacy in prophylactic settings and severe cases, solidifying its role in modern infectious disease management.